Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: J Immunol. 2010 Jun 25;185(3):1878–1886. doi: 10.4049/jimmunol.1001305

Figure 4. PECAM translocates to DRMs after cross-linking.

Figure 4

(A) Differentiated U937L cells were stimulated by PECAM cross-linking for 3 minutes followed by lysis in cold Triton buffer. Soluble proteins in the supernatant (S) and insoluble proteins in the pellet (I) were analysed by western blotting using antibodies against PECAM, CD64, CD32 and actin. Quantification of levels of PECAM from each fraction is shown below, data are from 7 separate experiments. (B) Soluble and insoluble fractions from U937L cells stimulated for increasing times by PECAM cross-linking were probed for PECAM. (C) U937L cells were left untreated or pretreated with 20μM MβCDX for 45min before undergoing PECAM cross-linking for 3 minutes. Lysates were run over a sucrose density gradient and fractions probed for PECAM or Lyn kinase by western blotting. (D) Purified human monocytes with or without MβCDX pretreatment were stimulated by PECAM cross-linking for 3 minutes followed by lysis in cold Triton buffer. Soluble and insoluble fractions were analysed by western blotting using antibodies against PECAM.